Skip to main content
Publications
Wang SV, Pottegard A, Crown W, Arlett P, Ashcroft DM, Benchimol EI, Berger ML, Crane G, Goettsch W, Hua W, Kabadi S, Kern DM, Kurz X, Langan S, Nonaka T, Orsini L, Perez-Gutthann S , Pinheiro S, Pratt N, Schneeweiss S, Toussi M, Williams RJ. HARmonized protocol template to enhance reproducibility of hypothesis evaluating real-world evidence studies on treatment effects: a good practices report of a joint ISPE/ISPOR Task Force . Value Health. 2022 Oct 1;25(10):1663-72. doi: 10.1016/j.jval.2022.09.001
Herring W , Gould IG, Casamassima G, Dort T, Zhang Y, Acosta C, Hyde R, Spelman T, Butzkueven H. A cost-effectiveness analysis using real-world data from the MSBase Registry: comparing natalizumab to fingolimod in patients with inadequate response to disease-modifying therapies in relapsing-remitting multiple sclerosis in Italy . Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain. [abstract] Value Health. 2018 Oct; 21(Suppl 3):S338.
Herring W , Gould IG, Ruiz L, Dort T, Zhang Y, Acosta C, Hyde R, Spelman T, Butzkueven H. A cost-effectiveness analysis using real-world data from the MSBase Registry: comparing natalizumab to fingolimod in patients with inadequate response to disease-modifying therapies in relapsing-remitting multiple sclerosis in Spain . Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain. [abstract] Value Health. 2018 Oct; 21(Suppl 3):S338.
Trantham L, Klein AB, Parikh RC , Kurosky S, Zhang Y, Levine CA, Kaye JA. Unresectable, locally advanced, stage III non-small cell lung cancer: real-world clinical characteristics, treatment patterns, and health care resource utilization in Europe . Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S49. doi: 10.1016/j.jval.2018.04.289
Kurosky S, Klein AB, Parikh RC , Trantham L, Zhang Y, Levine CA, Kaye JA. Clinical characteristics, treatment patterns, and health care resource utilization in unresectable, locally advanced, stage III non-small cell lung cancer: a medical record review study in the United States and Canada . Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S49. doi: 10.1016/j.jval.2018.04.286
Hollis K , Abuzakouk M, Balp M, Berard F, Canonica GW, Gimenez-Arnau A, Grattan C, Khalil S, Knulst AC, Lacour J, Lynde C, Maurer M, Mcbride D, Nakonechna A, Ortiz De Frutos J, Oude Elberink J, Proctor C, Sussman G, Sweeney C, Tian H, Weller K, Marsland A. Assessing health-utility values for chronic spontaneous/idiopathic urticaria in real-world using the EQ-5D: results from ASSURE-CSU study . Poster presented at the 2016 ISPOR 19th Annual European Congress; November 1, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A570-1.
Ajmera MR, Davis KL , Price G, Li L, Huang YJ, Price GL, Goyal RK , John WJ, Cuyun Carter G, Kaye JA, Boye ME. Economic outcomes associated with tumor histology among elderly patients with metastatic non–small cell lung cancer . Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 24, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A165.
Mcbride D, Abuzakouk M, Balp M-M, Berard F, Canonica GW, Gimenez-Arnau A, Grattan C, Hollis K , Khalil S, Knulst A, Lacour J-P, Lynde C, Marsland A, Nakonechna A, Ortiz De Frutoz FJ, Oude Elberink JNG, Proctor C, Sussman G, Weller K, Maurer M. ASSURE-CSU: assessing the impact of chronic spontaneous/idiopathic urticaria on work productivity and activity . Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 23, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A124-5.